Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells

Journal of Immunology

Volumn 169, Issue 10, 2002, Pages 5424-5432

  Noessner, Elfriede ^a   Gastpar, Robert ^a   Milani, Valeria ^a   Brandl, Anna ^a   Hutzler, Peter J S ^a   Kuppner, Maria C ^a   Roos, Miriam ^a   Kremmer, Elisabeth ^a   Asea, Alexzander ^a   Calderwood, Stuart K ^a   Issels, Rolf D ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; PEPTIDE; RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL METABOLISM; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOTHERAPY; ISOELECTRIC FOCUSING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; VACCINATION;

EID: 0037111218     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.10.5424     Document Type: Article

References (58)

1. Srivastava, P. K., and H. Udono. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:728.
2. Suto, R., and P. K. Srivastava. 1995. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269:1585.
3. Schild, H., D. Arnold-Schild, E. Lammert, and H. G. Rammensee. 1999. Stress proteins and immunity mediated by cytotoxic T lymphocytes. Curr. Opin. Immunol. 11:109.
4. Tamura, Y., P. Peng, K. Liu, M. Daou, and P. K. Srivastava. 1997. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117.
5. Janetzki, S., D. Palla, V. Rosenhauer, H. Lochs, J. J. Lewis, and P. K. Srivastava. 2000. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study. Int. J. Cancer 88:232.
6. Srivastava, P. K. 2001. Immunotherapy of human cancer: Lessons from mice. Nat. Immunol. 5:363.
7. Srivastava, P. K. 2002. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2:185.
8. + T cells in vivo. Proc. Natl. Acad. Sci. USA 91:3077.
9. Young, J. W. 1999. Dendritic cells: Expansion and differentiation with hematopoietic growth factors. Curr. Opin. Hematol. 6:135.
10. Banchereau, J., F. Briere, C. Caux, J. Davouost, S. Lebecque, Y.-J. Liu, B. Pulendran, and K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.
11. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, and H. Kosaka. 1996. Constitutive class 1-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.
12. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187:1555.
13. Singh-Jasuja, H., R. E. M. Toes, P. Spee, C. Münz, N. Hilf, S. P. Schoenberger, P. Ricciardi-Castagnoli, J. Neefjes, H. G. Rammensee, D. Arnold-Schild, and H. Schild. 2000. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J. Exp. Med. 191:1965.
14. Arnold-Schild, D., D. Hanau, D. Spehner, C. Schmid, H. G. Rammensee, H. de la Salle, and H. Schild. 1999. Cutting edge: Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 162:3757.
15. + cells. J. Immunol. 165:2582.
16. Basu, S., R. J. Binder, T. Ramalingam, and P. K. Srivastava. 2001. CD91: CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70 and calreticulin. Immunity 14:303.
17. Binder, R. J., D. K. Han, and P. K. Srivastava. 2000. CD91: A receptor for heat shock protein gp96. Nat. Immunol. 1:151.
18. Srivastava, P. K., A. B. DeLeo, and L. J. Old. 1986. Tumor rejection antigens of chemically induced sarcomas in inbred mice. Proc. Natl. Acad. Sci. USA 83:3407.
19. Udono, H., and P. K. Srivastava. 1993. Heat shock protein 70-associated peptides elicit specific cancer immunity. J. Exp. Med. 178:1391.
20. Udono, H., and P. K. Srivastava. 1994. Comparison of tumor-specific immuno-genicities of stress-induced proteins gp96, HSP90 and HSP70. J. Immunol. 152:5398.
21. b-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. Eur. J. Immunol. 28:1016.
22. Blachere, N. E., Z. Li, R. Y. Chandawarkar, R. Suto, N. S. Jaikaria, S. Basu, H. Udono, and P. K. Srivastava. 1997. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1315.
23. Ciupitu, A. M., M. Petersson, C. L. O'Donnell, K. Williams, S. Jindal, R. Kiessling, and R. M. Welsh. 1998. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 187:685.
24. 2 in transgenic adenocarcinoma of mouse prostata cells. Cancer Res. 60:4714.
25. Menoret, A., and R. Chandawarkar. 1998. Heat-shock protein-based anticancer immunotherapy: An idea whose time has come. Semin. Oncol. 25:654.
26. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, and J. Ruppert. 1994. The relationship between class 1 binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
27. Riker, A. I., U. S. Kammula, M. C. Panelli, E. Wang, G. A. Ohnmacht, S. M. Steinberg, S. A. Rosenberg, and F. M. Marincola. 2000. Threshold levels of gene expression of the melanoma antigen gp100, correlate with tumor cell recognition by cytotoxic T lymphocytes. Int. J. Cancer 86:818.
28. Rivoltini, L., K. C. Barracchini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class 1 allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
29. McMichael, A. J., P. Parham, N. Rust, and F. Brodsky. 1980. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum. Immunol. 1:121.
30. Visseren, M. J., A. van Elsas, E. I. van der Voort, M. E. Ressing, W. M. Kast, P. I. Schrier, and C. J. Melief. 1995. CTL specific for tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154:3991.
31. Peng, P., A. Menoret, and P. K. Srivastava. 1997. Purification of immunogenic heat shock protein-peptide complexes by ADP-affinity chromatography. J. Immunol. Methods 204:3.
32. + T cells to tumor cell antigens by dendritic cells. J. Immunol. 168:108.
33. Asea, A., S.-K. Kraeft, E. A. Kurt-Jones, M. A. Stevenson, L. B. Chen, R. W. Finberg, G. C. Koo, and S. K. Calderwood. 2000. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat. Med. 6:435.
34. Kuppner, M. C., R. Gastpar, S. Gelwer, E. Noessner, O. Ochmann, A. Scharner, and R. D. Issels. 2001. The role of heat shock protein (HSP70) in dendritic cell maturation: HSP70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors. Eur. J. Immunol. 31:1602.
35. Vabulas, R. M., P. Ahmad-Nejad, S. Ghose, C. J. Kirschning, R. D. Issels, and H. Wagner. 2002. HSP70 as endogenous stimulus of Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 277:15107.
36. Asea, A., M. Rehli, E. Kabingu, J. A. Boch, O. Bare, P. E. Auron, M. A. Stevenson, and S. K. Calderwood. 2002. Novel signal transduction pathway utilized by extracellular HSP70: Role of TLR2 and TLR4. J. Biol. Chem. 277:15028.
37. Somersan, S., M. Larsson, J. Fonteneau, S. Basu, P. Srivastava, and N. Bhardway. 2001. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J. Immunol. 167:4844.
38. Todryk, S., A. A. Melcher, N. Hardwick, E. Linardakis, A. Bateman, M. P. Colombo, A. Stoppacciaro, and R. G. Vile. 1999. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol. 163:1398.
39. Multhoff, G., C. Botzler, L. Jennen, J. Schmidt, J. Ellwart, and R. D. Issels. 1997. Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. J. Immunol. 158:4341.
40. Multhoff, G., L. Mizzen, C. C. Winchester, C. M. Milner, S. Wenk, G. Eissner, H. H. Kampinga, B. Laumbacher, and J. Johnson. 1999. Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Exp. Hematol. 27:1627.
41. Albert, M. L., S. F. Pearce, L. M. Francisco, B. Sauter, P. Roy, R. L. Silverstein, and N. Bhardwaj. 1998. Immature dendritic cells phagocytose apoptotic cells via α,β and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188:1359.
42. Srivastava, P. K., A. Menoret, S. Basu, R. J. Binder, and K. L. McQuade. 1998. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity 8:657.
43. Chen, W., U. Syldath, K. Bellmann, V. Burkart, and H. Kolb. 1999. Human 60-kDa heat-shock protein: A danger signal to the innate immune system. J. Immunol. 162:3212.
44. Kol, A., A. H. Lichtman, R. W. Finberg, P. Libby, and E. A. Kurt-Jones. 2000. Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J. Immunol. 164:13.
45. Singh-Jasuja, H., H. U. Scherer, N. Hilf, D. Arnold-Schild, H. G. Rammensee, R. E. M. Toes, and H. Schild. 2000. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30:2211.
46. + cells in vivo. J. Immunol. 165:6029.
47. Zheng, H., J. Dai, D. Stoilova, and Z. Li. 2001. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J. Immunol. 167:6731.
48. Protti, M. P., S. Heltai, M. Bellone, M. Ferrarini, A. A. Manfredini, and C. Rugarli. 1994. Constitutive expression of the heat shock protein 72 kDa in human melanoma cells. Cancer Lett. 85:211.
49. Castelli, C., A. T. Ciupitu, F. Rini, L. Rivoltini, A. Mazzocchi, R. Kiessling, and G. Parmiani. 2001. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res. 61:222.
50. Heath, W. R., and F. R. Carbone. 1999. Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 11:314.
51. Binder, R. J., N. E. Blachere, and P. K. Srivastava. 2001. Heat shock protein-chaperoned peptides but not free peptides introduced in the cytosol are presented efficiently by major histocompatibility complex I molecules. J. Biol. Chem. 276:17163.
52. Falk, M. H., and R. D. Issels. 2001. Hyperthermia in oncology. Int. J. Hyperthermia 17:1.
53. Wust, P., B. Hildebrandt, G. Sreenivasa, B. Rau, H. Riess, R. Felix, and P. M. Schlag. 2002. Hyperthermia in combined treatment of cancer. Lancet Oncol. 3:487.
54. Overgaard, J., D. Gonzales, M. C. C. M. Hulshof, G. Arcangeli, O. Dahl, and S. M. Bentzen. 1995. Randomized trials of hyperthermia as adjuvant to radio-therapy for recurrent or metastatic malignant melanoma. Lancet 345:540.
55. Fuller, K. J., R. D. Issels, D. O. Slosman, J.-G. Guillet, T. Soussi, and B. S. Polla. 1994. Cancer and the heat shock response. Eur. J. Cancer 12:1884.
56. Basu, S., R. J. Binder, R. Suto, K. M. Anderson, and P. K. Srivastava. 2000. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the KF-κB pathway. Int. Immunol. 12:1539.
57. Melcher, A. A., S. Todryk, N. Hardwick, M. Ford, M. Jackobson, and R. G. Vile. 1998. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med. 4:581.
58. Wang, X.-Y., L. Kazim, E. A. Repasky, and J. R. Subjeck. 2001. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J. Immunol. 165:490.